tbuckley/cabot-search huggingface dataset:
Effect of dose on denileukin diftitox (Dd) response in treatment-naïve cutaneous T-cell lymphoma (CTCL) subjects: A retrospective analysis of three phase III studies
Authors: N. H. Dang, Y. Sun, J. Gao
Journal: Journal of Clinical Oncology (2009)

e19509 Background: Three phase III studies (10, 11, 14) have been conducted with Dd, a novel IL-2 receptor-targeted recombinant fusion protein, in subjects with CTCL. Dd is approved for the treatment of persistent/recurrent CD25(+) CTCL and is the most extensively studied agent in CTCL. We retrospectively analyzed the efficacy of two Dd doses in treatment-naïve CD25(+) CTCL subjects to understand the relationship between dose and response to therapy. Methods: Studies 10 and 11 included early or advanced stage CD25(+) subjects (CD25 immunostaining in &gt;20% of malignant cells) while 14 included CD25(-). Subjects received 9 or 18 mcg/kg/day IV for 5 days, repeating every 21 days for up to 8 courses; subjects in study 14 only received the higher dose. Study 11 included a placebo arm. Subject demographics were similar among the three studies and between the 2 dose groups in each. Response confirmation required ≥2 consecutive courses (3 observations) and was adjudicated by an independent Data Endpoint Review Committee in each study, using a weighted severity skin, blood and lymph node count. The primary endpoint was ORR (CR, CCR, PR) and the key secondary endpoint was progression-free survival (PFS). Results: Integrated efficacy results for ORR and PFS are shown in the table for treatment-naïve CD25(+) subjects. In general, the nature and incidence of the adverse events reported in the 3 studies were similar, with studies 11 and 14 proving to be broadly consistent with study 10 in terms of safety. Tolerability of 9 and 18 mcg/kg/d was similar in study 10. In study 11, the only AEs that were more frequent in the high-dose group were vomiting (13.3% vs 34.5%) and dysgeusia (0% vs 10.9%). Conclusions: Overall, there was a trend towards higher efficacy favoring 18 mcg/kg/day in treatment-naïve CD25(+) subjects. The ORR was statistically significant for the higher dose group. [Table: see text]
Methylation loci associated with body mass index, waist circumference, and waist-to-hip ratio in Chinese adults: an epigenome-wide analysis
Authors: Biqi Wang, Wenjing Gao, Jun Li, Canqing Yu, Weihua Cao, Jun Lv, Zengchang Pang, Liming Cong, Hua Wang, Xianping Wu, Liming Liang, Tangchun Wu, Liming Li
Journal: The Lancet (2016)
Application of the mantle international prognostic index (MIPI) to patients with mantle cell lymphoma treated with fludarabine/cyclophosphamide: Results from a UK NCRI Lymphoma Group study
Authors: S. Rule, P. Smith, W. Qian, J. Gambell, N. Curtis, P. Johnson, D. Linch
Journal: Journal of Clinical Oncology (2009)

8555 Background: Mantle cell lymphoma (MCL) remains an incurable malignancy with conventional chemotherapeutic options with little randomised evidence to help direct therapy. The International Prognostic Index (IPI) for diffuse large cell lymphoma or Follicular Lymphoma International Prognostic Index (FLIPI) showed poor separation of survival curves in MCL patients. A new prognostic index (MIPI) based on age, performance status, lactate dehydrogenase (LDH), and leukocyte count was developed for patients with advanced stage MCL. Data from a randomised phase II NCRI trial designed to assess the effect of adding rituximab to an all oral chemotherapy regimen has been used to validate the MIPI. Methods: Patients with advanced stage, newly diagnosed MCL were randomised to receive either oral fludarabine 40mg/m 2 and cyclophosphamide 250mg/m 2 daily x 3 repeated every 28 days (FC) or FC with standard dose rituximab (375mg/m 2 on day 1 of every cycle) (FCR). Patients could receive up to 8 cycles of treatment but no consolidation therapy was permitted. The primary outcome measures were response rate and the feasibility of a phase III randomised study. Results: 156 patients were randomised. Median age 64 (36–88) with a significant male predominance. With median follow up of 49 months for survivors the five year overall survival (OS) is 39%. 117 patients had complete data for calculating the simplified Mantle International Prognostic Index (MIPI) .There was equal distribution between the 3 risk groups (low risk 35%, intermediate risk 33% and high risk 31%). The median OS (months) for the 3 groups is; low not reached, intermediate 55.7 and high 20.4 (p of log rank test = 0.0048). However there is no difference between the 3 groups with regard to progression free survival (p=0.31). Conclusions: This large study of patients treated with an oral purine analogue combination confirms that the MIPI is predictive for OS. However MIPI does not discriminate for PFS suggesting that those patients with high scores have an inferior response to subsequent therapy post relapse after FC based therapy. No significant financial relationships to disclose.
Recombinant Human Thrombopoietin (rh-TPO) in Combination with Rituximab As a Novel Therapy in Corticosteroid-Resistant Primary Immune Thrombocytopenia (ITP)
Authors: Li Guo, Xiaoyuan Dong, Jie Li, Danyan Ji, Ping Qin, Jun Peng, Ruirong Xu, Xin Wang, Yuhong Zhou, Ming Hou
Journal: Blood (2011)
Fibrous Cap Thickness by Optical Coherence Tomography In Vivo
Authors: Annapoorna S. Kini, Yuliya Vengrenyuk, Takahiro Yoshimura, Mitsuaki Matsumura, Jacobo Pena, Usman Baber, Pedro Moreno, Roxana Mehran, Akiko Maehara, Samin Sharma, Jagat Narula
Journal: Journal of the American College of Cardiology (2016)
PROTESIS PALIATIVAS DE COLON: SERIE DE 216 PACIENTES EN LOS ULTIMOS 12 AÑOS
Authors: D Tardáguila, B Alvarez Suárez, A López Baz, A Dacal, E Martí, A Fernández López, E Castro, R González Soler, A González Ramírez, L López Rosés
Journal: Endoscopy (2016)

Introducción: La obstrucción intestinal como debut del cáncer colorrectal se ha tratado tradicionalmente con intervención quirúrgica urgente. La colocación de prótesis colónicas de manera paliativa es la alternativa eficaz y aceptada en la actualidad.
TCT-514 Comparison of angiographic scores and fractional myocardial mass: Use of fractional myocardial mass for comprehensive evaluation of coronary artery disease
Authors: Hyung Yoon Kim, Joon-Hyung Doh, Hong-Seok Lim, Myeong-Ho Yoon, Doo Kyoung Kang, Chang-Wook Nam, Bon-Kwon Koo, Eun Kyoung Kim, Seung-Jea Tahk, Eun-Seok Shin, Sung Mok Kim, Yeonhyeon Choe, Jin-Ho Choi
Journal: Journal of the American College of Cardiology (2016)
TERAPIA COMBINADA CON ELECTROINCISIÓN Y DILATACIÓN NEUMÁTICA EN ESTENOSIS BENIGNAS DE ANASTOMOSIS COLÓNICAS POSTQUIRÚRGICAS. SERIE DE 15 CASOS
Authors: E Tenorio González, IL Pinazo Martínez, L Vázquez Pedreño, O Sánchez García, E Omonte Guzmán, M Bocanegra Viniegra, E Morcillo Jiménez, A Rico Cano, H Flores Moreno, M Jiménez Pérez
Journal: Endoscopy (2016)

Introducción: El desarrollo de estenosis benignas en anastomosis tras cirugía colorrectal es un desafío terapéutico por su alta tasa de recidiva, siendo la terapia incisional asociada a dilatación neumática una alternativa a las técnicas habituales.
TCT-619 Periprocedural Intracardiac Echocardiography from the Left Atrium for Left Atrial Appendage Occlusion with the Amplatzer Cardiac PlugTM
Authors: Zied FRIKHA, Ayoub El hammiri, Jeannot Potvin, Jean-Marc Raymond, Jean-Bernard Masson
Journal: Journal of the American College of Cardiology (2016)
O017A : Non-invasive tools and risk of varices and clinically significant portal hypertension in compensated cirrhosis: the “anticipate” study
Authors: J.G. Abraldes, C. Bureau, H. Stefanescu, S. Augustin, M. Ney, B. Procopet, J. Bosch, J. Genesca, A. Berzigotti
Journal: Journal of Hepatology (2015)
TCT-38 Paravalvular Regurgitation Regression and Impact on 1-year Outcomes After Transcatheter Aortic Valve Replacement with the SAPIEN 3 Transcatheter Valve
Authors: Philippe Pibarot, Rebecca Hahn, Neil Weissman, Marie Arsenault, Jonathan Beaudoin, Mathieu Bernier, Abdellaziz Dahou, Omar Khalique, Federico Asch, Oumhani Toubal, Jonathon Leipsic, Philipp Blanke, Feifan Zhang, Rupa Parvataneni, Howard Herrmann, Martin Leon, Vinod Thourani, Susheel Kodali
Journal: Journal of the American College of Cardiology (2016)
WT1 Gene Expression Limited Application for MRD Monitoring in AML Patients Carrying MLL Rearrangements.
Authors: Grigory Tsaur, Alexander Popov, Alexander Druy, Anna Ivanova, Tatyana Riger, Olga Plekhanova, Yulia Svechnikova, Egor Shorikov, Claus Meyer, Rolf Marschalek, Leonid Saveliev, Larisa Fechina
Journal: Blood (2009)
The inter-relationship of hypoxia and phospho-Akt in the pathobiology of malignant pleural mesothelioma
Authors: D. Stewart, J. Edwards, D. Richardson, L. Jones, B. Burke, D. Waller, L. Zeigler-Heitbrock, A. Wardlaw, K. O’Byrne
Journal: Journal of Clinical Oncology (2006)

17057 Background: Poor outcomes with conventional oncological treatments for malignant pleural mesothelioma (MPM) have driven the imperative to advance understanding of the disease pathobiology. Carbonic Anhydrase (CA)-IX is a surrogate marker of hypoxia over-expressed in solid tumours. Protein Kinase B, or Akt, known to have important intracellular roles including resistance to apoptosis, is activated in human malignancies and upregulated in hypoxic conditions. This study examined the expression of CA-IX and phosphorylated Akt (pAkt) in tumour samples from patients with MPM, correlating expression with established prognostic factors. The role of pAkt in the survival of an MPM cell line exposed to hypoxic conditions was also examined. Methods: Full local regional ethics committee approval was obtained for this work. Tumour samples from 200 patients with MPM were stained using pAkt and CA-IX specific antibodies. The effect of hypoxia on Akt and pAkt was evaluated in the JU77 mesothelioma cell line in the presence or absence of the phosphatidylinositol-3-kinase inhibitor, LY294002. Results: There was a positive association between the level of CA-IX and pAkt staining, implying that intra-tumoural hypoxia may be a stimulus for Akt phosphorylation. On multivariate analysis increased expression of nuclear pAkt was found to be associated with a poor survival. In-vitro cell culture work showed that, although pAkt is expressed in normoxic conditions in the JU77 cell line, the rates of apoptosis were significantly increased in hypoxic conditions when the phosphorylation of Akt was blocked by LY294002. Conclusions: This work provides evidence for the anti-apoptotic role of pAkt in hypoxic conditions in solid human malignancies. Phospho-Akt may represent a novel therapeutic target in MPM. No significant financial relationships to disclose.
Treatment of Left Main Coronary Artery Disease
Authors: Eugene Braunwald
Journal: New England Journal of Medicine (2016)

When coronary arteriography was developed in the early 1960s, the very high risk associated with obstructive left main coronary artery disease became evident; this risk was related to the large volume of myocardium supplied by this vessel. Among patients receiving the medical therapy available at the time, the 5-year mortality approached 60%, and the survivors usually had severe symptoms, including angina, heart failure, or both.1 Several years later, after coronary-artery bypass grafting (CABG) became available, two multicenter, randomized trials that compared medical treatment with surgical treatment showed that surgical treatment was strikingly superior.2,3 Since then, there has been general . . .
Intramyocardial Stem Cell Injection in Patients With Ischemic Cardiomyopathy
Authors: Adam R. Williams, Barry Trachtenberg, Darcy L. Velazquez, Ian McNiece, Peter Altman, Didier Rouy, Adam M. Mendizabal, Pradip M. Pattany, Gustavo A. Lopera, Joel Fishman, Juan P. Zambrano, Alan W. Heldman, Joshua M. Hare
Journal: Circulation Research (2011)

Transcatheter, intramyocardial injections of bone marrow-derived cell therapy produces reverse remodeling in large animal models of ischemic cardiomyopathy.We used cardiac MRI (CMR) in patients with left ventricular (LV) dysfunction related to remote myocardial infarction (MI) to test the hypothesis that bone marrow progenitor cell injection causes functional recovery of scarred myocardium and reverse remodeling.Eight patients (aged 57.2±13.3 years) received transendocardial, intramyocardial injection of autologous bone marrow progenitor cells (mononuclear or mesenchymal stem cells) in LV scar and border zone. All patients tolerated the procedure with no serious adverse events. CMR at 1 year demonstrated a decrease in end diastolic volume (208.7±20.4 versus 167.4±7.32 mL; P=0.03), a trend toward decreased end systolic volume (142.4±16.5 versus 107.6±7.4 mL; P=0.06), decreased infarct size (P<0.05), and improved regional LV function by peak Eulerian circumferential strain in the treated infarct zone (-8.1±1.0 versus -11.4±1.3; P=0.04). Improvements in regional function were evident at 3 months, whereas the changes in chamber dimensions were not significant until 6 months. Improved regional function in the infarct zone strongly correlated with reduction of end diastolic volume (r(2)=0.69, P=0.04) and end systolic volume (r(2)=0.83, P=0.01).These data suggest that transcatheter, intramyocardial injections of autologous bone marrow progenitor cells improve regional contractility of a chronic myocardial scar, and these changes predict subsequent reverse remodeling. The findings support the potential clinical benefits of this new treatment strategy and ongoing randomized clinical trials.
TCT-160 Impact of admission during ON vs. OFF hours in unselected ST-Elevation Myocardial Infarction Patients treated with Primary Percutaneous Coronary Intervention.
Authors: Anis SAIB, laurent Payot, Mathieu kerneis, Olivier Barthelemy, Jean-Philippe Collet, Claude Le Feuvre, Gérard Helft, remi choussat, Johanne Silvain, Gilles Montalescot
Journal: Journal of the American College of Cardiology (2016)
TCT-324 Mortality of Stenting Versus Bypass Surgery According to Completeness of Revascularization In Severe Coronary Artery Disease: Patient-Level Pooled Analysis of SYNTAX, PRECOMBAT, and BEST Trials
Authors: Jung-Min Ahn, Min Soo Cho, Se Hun Kang, Duk-Woo Park, Cheol Whan Lee, Mineok Chang, Rafael Cavalcante, Yohei Sotomi, Yoshinobu Onuma, ERHAN TENEKECIOGLU, Pil Hyung Lee, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Seong-Wook Park, Patrick Serruys, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2016)
High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells
Authors: Bastien Gerby, Diogo F.T. Veiga, Jana Krosl, Sami Nourreddine, Julianne Ouellette, André Haman, Geneviève Lavoie, Iman Fares, Mathieu Tremblay, Véronique Litalien, Elizabeth Ottoni, Milena Kosic, Dominique Geoffrion, Joël Ryan, Paul S. Maddox, Jalila Chagraoui, Anne Marinier, Josée Hébert, Guy Sauvageau, Benjamin H. Kwok, Philippe P. Roux, Trang Hoang
Journal: Journal of Clinical Investigation (2016)

Current chemotherapies for T cell acute lymphoblastic leukemia (T-ALL) efficiently reduce tumor mass. Nonetheless, disease relapse attributed to survival of preleukemic stem cells (pre-LSCs) is associated with poor prognosis. Herein, we provide direct evidence that pre-LSCs are much less chemosensitive to existing chemotherapy drugs than leukemic blasts because of a distinctive lower proliferative state. Improving therapies for T-ALL requires the development of strategies to target pre-LSCs that are absolutely dependent on their microenvironment. Therefore, we designed a robust protocol for high-throughput screening of compounds that target primary pre-LSCs maintained in a niche-like environment, on stromal cells that were engineered for optimal NOTCH1 activation. The multiparametric readout takes into account the intrinsic complexity of primary cells in order to specifically monitor pre-LSCs, which were induced here by the SCL/TAL1 and LMO1 oncogenes. We screened a targeted library of compounds and determined that the estrogen derivative 2-methoxyestradiol (2-ME2) disrupted both cell-autonomous and non-cell-autonomous pathways. Specifically, 2-ME2 abrogated pre-LSC viability and self-renewal activity in vivo by inhibiting translation of MYC, a downstream effector of NOTCH1, and preventing SCL/TAL1 activity. In contrast, normal hematopoietic stem/progenitor cells remained functional. These results illustrate how recapitulating tissue-like properties of primary cells in high-throughput screening is a promising avenue for innovation in cancer chemotherapy.
CONSECUENCIAS CLÍNICAS Y ECONÓMICAS DE LA ABLACIÓN POR RADIOFRECUENCIA EN PACIENTES CON ESÓFAGO DE BARRETT CON DISPLASIA DE BAJO GRADO EN ESPAÑA
Authors: JM Estéban López-Jamar, P González Carro, J Gornals Soler, C Collados Clares, M Álvarez Orozco, A Pérez Mirtu, S Serip
Journal: Endoscopy (2016)

Introducción: El tratamiento de elección para el Esófago de Barrett (EB) con displasia de bajo grado (DBG) puede influir en el resultado clínico del paciente y suponer un beneficio importante para el Sistema Nacional de Salud (SNS) español.
Submyeloablative Allografts for Hematologic Malignancies: Validation of a Prognostic Model Based on Pre-Transplant Variables.
Authors: Jayesh Mehta, Jane Winter, Martin Tallman, Leo Gordon, Stephanie Williams, Olga Frankfurt, Andrew Evens, David Grinblatt, Lynne Kaminer, Richard Meagher, Seema Singhal
Journal: Blood (2006)
Autophagy Inhibition Overcomes Resistance to Cytosine Arabinoside in Acute Myeloid Leukemia Cells through Inducing Autophagic Cell Death and Intrinsic Pathway Apoptosis
Authors: Yundeok Kim, Ju-In Eom, Hoi-Kyung Jeung, Jieun Jang, Jin Seok Kim, June-Won Cheong, Young Sam Kim, Yoo Hong Min
Journal: Blood (2014)
MINI01.06: Circulating Angiogenesis Biomarkers are Predictive for Early Stage Non–Small Cell Lung Cancer Progression and Clinical Outcome
Authors: Imad Tarhoni, Cristina Fhied, Ravi Pithadia, Christopher W. Seder, Sanjib Basu, Michael Liptay, Jeffrey A. Borgia
Journal: Journal of Thoracic Oncology (2016)
Incentivizing Data Sharing and Collaboration in Medical Research—The S-Index
Authors: Mark Olfson, Melanie M. Wall, Carlos Blanco
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Response to Dr Nikpour's letter
Authors: Theresa R Wilhelm, Laurence S Magder, Michelle Petri
Journal: Annals of the Rheumatic Diseases (2016)

Remission in systemic lupus erythematosus: durable remission is rare'. 2 We agree that the lupus low disease activity state (LLDAS) is associated with less long-term damage.We are convinced that true remission should be our ultimate treatment goal.For example, LLDAS allows up to 7.5 mg of prednisone daily, while it was shown that prednisone doses above 6 mg/day significantly increase the risk of later organ damage by 50%. 3 Very few patients reach durable remission, regardless of defining remission on treatment or off treatment.Remission is a high bar to aim for with our current treatment strategies.
Significance of Conventional Cytogenetics in Improving the Diagnosis and Prognosis of Lymphoid Neoplasms in Tissue Samples
Authors: Aurelia Meloni-Ehrig, Christine A. Curtis, Sean P. Mahoney, Nathan Bohls, Claudia Kraemer, Elizabeth Stone, Jean Braun, Kaye Siragusa, Patricia Stone, Adrienne Ramos, Christopher Thompson, Fred Daugherty, Steve Conklin, Caroline An, Lalarukh Aftab, Amir Hammami, Stephanie Schniederjan, Zhenjun Lou, Zunyan Dai, Jill Lyons, Lawrence Hertzberg
Journal: Blood (2015)
Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years — United States, 2015
Authors: James M. Dahlhamer, Emily P. Zammitti, Brian W. Ward, Anne G. Wheaton, Janet B. Croft
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Crohn's disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), are characterized by chronic inflammation of the gastrointestinal tract (1). IBD has been associated with poor quality of life and extensive morbidity and often results in complications requiring hospitalizations and surgical procedures (2-4). Most previous studies of IBD have used administrative claims data or data collected from limited geographic areas to demonstrate increases in estimated prevalence of IBD within the United States (5,6). Few national prevalence estimates of IBD among adults based on large, nationally representative data sources exist, and those that do tend to be based on older data. For example, the most recent national study used 1999 National Health Interview Survey (NHIS) data and estimated that 1.8 million (0.9%) U.S. adults had IBD (7). To examine the prevalence of IBD among the civilian, noninstitutionalized U.S. adult population, data from the 2015 NHIS were analyzed. Overall, an estimated 3.1 million, or 1.3%, of U.S. adults have received a diagnosis of IBD. Within population subgroups, a higher prevalence of IBD was identified among adults aged ≥45 years, Hispanics, non-Hispanic whites, and adults with less than a high school level of education, not currently employed, born in the United States, living in poverty, or living in suburban areas. The use of a nationally representative data source such as the NHIS to estimate the prevalence of IBD overall and by population subgroups is important to understand the burden of IBD on the U.S. health care system.
TCT-655 High Prevalence of TAVR Leaflet Thrombosis in a Single Center Pathological Review
Authors: Fernanda Mangione, Tannas Jatene, Alexandra Gonçalves, Gregory Fishbein, Richard Mitchell, Tsuyoshi Kaneko, Pinak Shah, Ron Blankstein, Robert Padera, Deepak Bhatt
Journal: Journal of the American College of Cardiology (2016)
TCT-269 Impact of Incomplete Revascularization in Diabetes Mellitus Patients with Multivessel Disease Treated with Percutaneous Coronary Intervention
Authors: Sang Yeub Lee, Hector M. Garcia-Garcia, Kayode Kuku, Viana Azizi, Arie Steinvil, Toby Rogers, Sarkis Kiramijyan, Smita I. Negi, Jiaxiang Gai, Rebecca Torguson, Lowell Satler, Augusto Pichard, Ron Waksman
Journal: Journal of the American College of Cardiology (2016)